Christopher Ryan Sullivan - 07 May 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: AVTX
Reported as of: 07 May 2026
Net transaction value: -$448,818
SEC form: 4
Accepted by SEC: 11 May 2026, 16:05:09 UTC
Prior SEC filing: 07 May 2026
Next SEC filing: 26 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Sullivan

Key filing fact

Christopher Ryan Sullivan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 11 May 2026.

Key facts

This page summarizes Christopher Ryan Sullivan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 07 May 2026.
Current net transaction value: -$448,818.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001810417 Primary reporting owner

Sullivan Christopher Ryan

Relationship: Chief Financial Officer
Address: C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
Signature: /s/ Christopher Sullivan
Signature date: 11 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +18,606
Change %: +4399%
Price: $9.88^*
Shares after: 19,029
Date: 07 May 2026
Ownership: Direct
Footnotes: F1

AVTX transaction

Common Stock

Sale

Transaction value: $448,818
Shares: -18,606
Change %: -98%
Price: $24.12
Shares after: 423
Date: 07 May 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -18,606
Change %: -10%
Price: $0.000000^*
Shares after: 168,094
Date: 07 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,606
Exercise price: $9.88
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

Footnote F2

The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Footnote F3

The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.